Cargando…

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and anomalous hyperplasia of connective tissue, and it may further develop into liver cirrhosis, liver failure or liver c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Zui, Sun, Hongbao, Xue, Taixiong, Gan, Cailing, Liu, Hongyao, Xie, Yuting, Yao, Yuqin, Ye, Tinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490799/
https://www.ncbi.nlm.nih.gov/pubmed/34621747
http://dx.doi.org/10.3389/fcell.2021.730176
_version_ 1784578597960286208
author Tan, Zui
Sun, Hongbao
Xue, Taixiong
Gan, Cailing
Liu, Hongyao
Xie, Yuting
Yao, Yuqin
Ye, Tinghong
author_facet Tan, Zui
Sun, Hongbao
Xue, Taixiong
Gan, Cailing
Liu, Hongyao
Xie, Yuting
Yao, Yuqin
Ye, Tinghong
author_sort Tan, Zui
collection PubMed
description Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and anomalous hyperplasia of connective tissue, and it may further develop into liver cirrhosis, liver failure or liver cancer. To date, chronic liver diseases accompanied with liver fibrosis have caused significant morbidity and mortality in the world with increasing tendency. Although early liver fibrosis has been reported to be reversible, the detailed mechanism of reversing liver fibrosis is still unclear and there is lack of an effective treatment for liver fibrosis. Thus, it is still a top priority for the research and development of anti-fibrosis drugs. In recent years, many strategies have emerged as crucial means to inhibit the occurrence and development of liver fibrosis including anti-inflammation and liver protection, inhibition of hepatic stellate cells (HSCs) activation and proliferation, reduction of ECM overproduction and acceleration of ECM degradation. Moreover, gene therapy has been proved to be a promising anti-fibrosis method. Here, we provide an overview of the relevant targets and drugs under development. We aim to classify and summarize their potential roles in treatment of liver fibrosis, and discuss the challenges and development of anti-fibrosis drugs.
format Online
Article
Text
id pubmed-8490799
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84907992021-10-06 Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy Tan, Zui Sun, Hongbao Xue, Taixiong Gan, Cailing Liu, Hongyao Xie, Yuting Yao, Yuqin Ye, Tinghong Front Cell Dev Biol Cell and Developmental Biology Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and anomalous hyperplasia of connective tissue, and it may further develop into liver cirrhosis, liver failure or liver cancer. To date, chronic liver diseases accompanied with liver fibrosis have caused significant morbidity and mortality in the world with increasing tendency. Although early liver fibrosis has been reported to be reversible, the detailed mechanism of reversing liver fibrosis is still unclear and there is lack of an effective treatment for liver fibrosis. Thus, it is still a top priority for the research and development of anti-fibrosis drugs. In recent years, many strategies have emerged as crucial means to inhibit the occurrence and development of liver fibrosis including anti-inflammation and liver protection, inhibition of hepatic stellate cells (HSCs) activation and proliferation, reduction of ECM overproduction and acceleration of ECM degradation. Moreover, gene therapy has been proved to be a promising anti-fibrosis method. Here, we provide an overview of the relevant targets and drugs under development. We aim to classify and summarize their potential roles in treatment of liver fibrosis, and discuss the challenges and development of anti-fibrosis drugs. Frontiers Media S.A. 2021-09-21 /pmc/articles/PMC8490799/ /pubmed/34621747 http://dx.doi.org/10.3389/fcell.2021.730176 Text en Copyright © 2021 Tan, Sun, Xue, Gan, Liu, Xie, Yao and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Tan, Zui
Sun, Hongbao
Xue, Taixiong
Gan, Cailing
Liu, Hongyao
Xie, Yuting
Yao, Yuqin
Ye, Tinghong
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title_full Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title_fullStr Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title_full_unstemmed Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title_short Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
title_sort liver fibrosis: therapeutic targets and advances in drug therapy
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490799/
https://www.ncbi.nlm.nih.gov/pubmed/34621747
http://dx.doi.org/10.3389/fcell.2021.730176
work_keys_str_mv AT tanzui liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT sunhongbao liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT xuetaixiong liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT gancailing liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT liuhongyao liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT xieyuting liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT yaoyuqin liverfibrosistherapeutictargetsandadvancesindrugtherapy
AT yetinghong liverfibrosistherapeutictargetsandadvancesindrugtherapy